PeptidePedia The community reference

Talk:FLOW trial

Discussion page·2 threads·no archives

This article is within the scope of the clinical evidence working group.

This is the discussion page for the article FLOW trial. It is for improving the article: sources, wording, structure, scope and titles. It is not a general discussion forum about the subject, and it is not a place to ask for advice — see Project:Medical disclaimer.

Early stopping inflates estimatesResolved

Trials stopped early for efficacy tend to overestimate effect. Stating it as a property of stopping rules rather than a criticism of this trial is the right handling. — FlowTrialFraser (talk) 09:45, 16 March 2026 (UTC)

Agreed, and it applies to every early-stopped trial a reader will encounter. ✓ Done — PreregPriya (talk) 13:20, 16 March 2026 (UTC)

Resolved. This thread is closed. Reopening it is fine if new sources appear; please add a new subsection rather than editing the closed discussion.

The initial eGFR dipDone

Readers regularly interpret the early fall as harm. Explaining that it is haemodynamic and pre-specified in the analysis is genuinely useful. — eGFR_Esme (talk) 10:30, 28 May 2026 (UTC)

Also worth linking from the eGFR article, which is where someone puzzled by their own trajectory would look. ✓ Done — LabRangeLindy (talk) 14:05, 28 May 2026 (UTC)

Done. This thread is closed. Reopening it is fine if new sources appear; please add a new subsection rather than editing the closed discussion.
This page was last edited on 28 May 2026, by LabRangeLindy. Text is available under the PeptidePedia Wiki Content Licence (PPCL-BY-SA 4.0).